Reneo Pharmaceuticals, Inc. (RPHM) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Irvine, CA, 美国. 现任CEO为 Gregory J. Flesher.
RPHM 拥有 IPO日期为 2021-04-08, 8 名全职员工, 在 NASDAQ Global Market, 市值为 $60.84M.
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
